Exclusive Interview

MDS' sites "perfectly dovetail" with Ricerca's capacity; VP

By Nick Taylor

- Last updated on GMT

Related tags President of the united states

MDS' sites "perfectly dovetail" with Ricerca's capacity; VP
The capabilities of the MDS Pharma Services' sites Ricerca is set to acquire "perfectly dovetail" with its existing capacity, according to a company vice president.

Speaking to Outsourcing-Pharma at Informex 2010, Mark Crane, vice president, business development and marketing at Ricerca, explained that services proivided by the MDS' sites take clients up to the developmental stage that Ricerca traditionally began working with companies.

Acquiring the MDS' sites increases Ricerca's headcount from 270 to over 800 and expands the company into new geographies. Despite this, Crane believes that integration will be relatively straightforward because of the lack of overlap between Ricerca's existing capacity and the acquired sites.

Related news

Show more

Related products

show more

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us

Products

View more

Webinars